Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Cancer

Volumn 112, Issue 7, 2008, Pages 1529-1537

  Sonneveld, Pieter ^a   Hajek, Roman ^b   Nagler, Arnon ^c   Spencer, Andrew ^d   Bladé, Joan ^e   Robak, Tadeusz ^f   Zhuang, Sen H ^g   Harousseau, Jean Luc ^h   Orlowski, Robert Z ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c SHEBA MEDICAL CENTER   (Israel)

^d ALFRED HOSPITAL   (Australia)

^e HOSPITAL CLÍNIC   (Spain)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g Ortho McNeil Pharmaceutical Incorporated   (United States)

^h HÔTEL DIEU   (France)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bortezomib; Lenalidomide; Multiple myeloma; Pegylated liposomal doxorubicin; Recurrent; Refractory; Thalidomide

Indexed keywords

BORTEZOMIB; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; LENALIDOMIDE; MITOXANTRONE; THALIDOMIDE;

ADULT; ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PYRAZINES; SALVAGE THERAPY; SURVIVAL RATE; THALIDOMIDE;

EID: 41149086836     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23326     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures, 2006. Atlanta, Ga: American Cancer Society, Inc.; 2006.
2. Ferlay J, Bray P, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.
3. Durie BG. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma. 2005;6:181-190.
4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
5. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17: 775-779.
6. Rajkumar SV, Dingli D, Nowakowski G, et al. Thalidomide and dexamethasone in newly diagnosed multiple myeloma: long-term results in patients not undergoing upfront autologous stem cell transplantation. Proc Am Soc Clin Oncol. 2005;23:593s. Abstract 6632.
7. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24: 431-436.
8. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(suppl 2):17-24.
9. Baz R, Choueiri TK, Jawde RA, et al. Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid® (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM). Blood. 2005;106:719a. Abstract 2559.
10. Padmanabhan S, Miller K, Musiel L, et al. Bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide is an active salvage regimen in patients with relapsed or refractory multiple myeloma: final results of a phase II study. Haematologica. 2006;91(suppl 1):277. Abstract 0752.
11. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81:889-895.
12. Hussein MA. Lenalidomide: patient management strategies. Semin Hematol. 2005;42:S22-S25.
13. THALOMID (thalidomide) Capsules [prescribing information]. Summit, NJ: Celgene Corporation; 2007.
14. Wang M, Knight R, Dimopoulos M, et al. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3553.
15. Wang M, Knight R, Dimopoulos M, et al. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma. Proc Am Soc Clin Oncol. 2006;24:427s. Abstract 7522.
16. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-3901.
17. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004;28:325-332.
18. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
19. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.